title: Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
abstract: Over the past ten years, proteasome inhibition has emerged as an effective therapeutic strategy for treating multiple myeloma (MM) and some lymphomas. In 2003, Bortezomib (BTZ) became the first proteasome inhibitor approved by the U.S. Food and Drug Administration (FDA). BTZ-based therapies have become a staple for the treatment of MM at all stages of the disease. The survival rate of MM patients has improved significantly since clinical introduction of BTZ and other immunomodulatory drugs. However, BTZ has several limitations. Not all patients respond to BTZ based therapies and relapse occurs in many patients who initially responded. Solid tumors, in particular, are often resistant to BTZ. Furthermore, BTZ can induce dose-limiting peripheral neuropathy (PN). The second generation proteasome inhibitor Carfizomib (CFZ; U.S. FDA approved in August 2012) induces responses in a minority of MM patients relapsed from or refractory to BTZ. There is less PN compared to BTZ. Four other second-generation proteasome inhibitors (Ixazomib, Delanzomib, Oprozomib and Marizomib) with different pharmacologic properties and broader anticancer activities, have also shown some clinical activity in bortezomib-resistant cancers. While the mechanism of resistance to bortezomib in human cancers still remains to be fully understood, targeting the immunoproteasome, ubiquitin E3 ligases, the 19S proteasome and deubiquitinases in pre-clinical studies represents possible directions for future generation inhibitors of ubiquitin-proteasome system in the treatment of MM and other cancers.
authors.forename: Q Ping
authors.initials: QP
authors.lastname: Dou
authors.affiliation: Barbara Ann Karmanos Cancer Institute and Department of Oncology, Wayne State University School of Medicine, 540.1 HWCRC, 4100 John R Road, Detroit, MI 48201. doup@karmanos.org.
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Zonder
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D000069286:Bortezomib; D015195:Drug Design; D006801:Humans; D058990:Molecular Targeted Therapy; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism*; D061988:Proteasome Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D059748:Proteolysis / Q000187:drug effects; D011719:Pyrazines / Q000009:adverse effects / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects; D043743:Ubiquitin-Protein Ligase Complexes / Q000378:metabolism; D044767:Ubiquitin-Protein Ligases / Q000378:metabolism; D064570:Ubiquitin-Specific Proteases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D054875:Ubiquitination / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D061988:Proteasome Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D043743:Ubiquitin-Protein Ligase Complexes; D044767:Ubiquitin-Protein Ligases; D064570:Ubiquitin-Specific Proteases; D046988:Proteasome Endopeptidase Complex
references.citation: Pharmacogenet Genomics. 2011 Mar;21(3):121-9
references.pmid: 21228734
references.citation: Leuk Lymphoma. 2009 May;50(5):716-22
references.pmid: 19347767
references.citation: Semin Hematol. 2012 Jul;49(3):258-62
references.pmid: 22726549
references.citation: Oncologist. 2012;17(5):694-707
references.pmid: 22566373
references.citation: Leukemia. 2013 Feb;27(2):430-40
references.pmid: 22763387
references.citation: Curr Pharm Des. 2013;19(22):4039-52
references.pmid: 23181570
references.citation: Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):3850-5
references.pmid: 10725400
references.citation: Front Biosci (Landmark Ed). 2012 Jan 01;17(5):1904-16
references.pmid: 22201844
references.citation: Blood. 2009 May 7;113(19):4667-76
references.pmid: 19050304
references.citation: Br J Haematol. 2010 Oct;151(1):47-53
references.pmid: 20735402
references.citation: Clin Cancer Res. 2010 Jan 15;16(2):719-26
references.pmid: 20068103
references.citation: Blood. 2012 Aug 2;120(5):947-59
references.pmid: 22645181
references.citation: Cell. 1994 Oct 7;79(1):13-21
references.pmid: 7923371
references.citation: Blood. 2009 Jul 30;114(5):1046-52
references.pmid: 19436050
references.citation: Clin Genitourin Cancer. 2007 Mar;5(4):278-83
references.pmid: 17553208
references.citation: Blood. 2009 Jun 11;113(24):6069-76
references.pmid: 19380866
references.citation: Invest New Drugs. 2011 Dec;29(6):1475-81
references.pmid: 20574790
references.citation: J Clin Oncol. 2013 Mar 1;31(7):923-9
references.pmid: 23129738
references.citation: Oncologist. 2003;8(6):508-13
references.pmid: 14657528
references.citation: Oncology (Williston Park). 2004 Dec;18(14 Suppl 11):14-21
references.pmid: 15688598
references.citation: Science. 2004 Oct 1;306(5693):117-20
references.pmid: 15459393
references.citation: Immunol Rev. 2005 Oct;207:19-30
references.pmid: 16181324
references.citation: Biochem Soc Trans. 2010 Feb;38(Pt 1):132-6
references.pmid: 20074047
references.citation: Biol Chem. 1997 Mar-Apr;378(3-4):131-40
references.pmid: 9165063
references.citation: Eur J Haematol. 2006 Sep;77(3):233-8
references.pmid: 16923110
references.citation: Blood. 2005 Apr 15;105(8):3058-65
references.pmid: 15626743
references.citation: J Clin Oncol. 2012 Feb 1;30(4):445-52
references.pmid: 22215754
references.citation: Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11364-9
references.pmid: 10500182
references.citation: J Biomed Biotechnol. 2011;2011:514261
references.pmid: 21765634
references.citation: Clin Cancer Res. 2008 Jun 1;14(11):3503-13
references.pmid: 18519783
references.citation: N Engl J Med. 2003 Jun 26;348(26):2609-17
references.pmid: 12826635
references.citation: Korean J Hematol. 2012 Mar;47(1):53-9
references.pmid: 22479278
references.citation: Haematologica. 2009 Aug;94(8):1044-8
references.pmid: 19644136
references.citation: Cancer Res. 2007 Jul 1;67(13):6383-91
references.pmid: 17616698
references.citation: J Clin Oncol. 2009 Oct 20;27(30):5015-22
references.pmid: 19738129
references.citation: Cancer Res. 2005 Jul 15;65(14):6282-93
references.pmid: 16024630
references.citation: J Clin Oncol. 2010 Nov 20;28(33):4976-84
references.pmid: 20956629
references.citation: Br J Haematol. 2007 Jul;138(2):176-85
references.pmid: 17593024
references.citation: Nat Rev Immunol. 2011 Nov 11;11(12):823-36
references.pmid: 22076556
references.citation: Leuk Lymphoma. 2011 Mar;52(3):394-9
references.pmid: 21323520
references.citation: Drug Discov Today. 2010 Mar;15(5-6):243-9
references.pmid: 20116451
references.citation: Cancer Res. 2005 Sep 1;65(17):7896-901
references.pmid: 16140960
references.citation: N Engl J Med. 2005 Jun 16;352(24):2487-98
references.pmid: 15958804
references.citation: Leuk Res. 2008 Nov;32(11):1661-8
references.pmid: 18394701
references.citation: Curr Hematol Malig Rep. 2012 Dec;7(4):258-66
references.pmid: 23065395
references.citation: Cancer Res. 2001 Feb 15;61(4):1280-4
references.pmid: 11245420
references.citation: Drug Resist Updat. 2008 Aug-Oct;11(4-5):164-79
references.pmid: 18818117
references.citation: Science. 2004 Feb 6;303(5659):844-8
references.pmid: 14704432
references.citation: J Clin Oncol. 2005 Sep 10;23(26):6345-50
references.pmid: 16155018
references.citation: N Engl J Med. 2008 Aug 28;359(9):906-17
references.pmid: 18753647
references.citation: Int J Oncol. 2008 Jul;33(1):129-36
references.pmid: 18575758
references.citation: Lancet. 2010 Dec 18;376(9758):2075-85
references.pmid: 21146205
references.citation: Mol Cancer. 2008 May 19;7:40
references.pmid: 18489772
references.citation: Cancer Treat Rev. 2012 Dec;38(8):968-80
references.pmid: 22226939
references.citation: Blood. 2010 Aug 5;116(5):679-86
references.pmid: 20385792
references.citation: Cancer Cell. 2013 Sep 9;24(3):289-304
references.pmid: 24029229
references.citation: Cancer Res. 2006 May 1;66(9):4758-65
references.pmid: 16651429
references.citation: J Clin Oncol. 2006 Oct 20;24(30):4867-74
references.pmid: 17001068
references.citation: Eur J Cancer. 2006 Jul;42(11):1564-73
references.pmid: 16765041
references.citation: Int J Cancer. 2006 Sep 1;119(5):971-9
references.pmid: 16557600
references.citation: Clin Cancer Res. 2008 Mar 15;14(6):1649-57
references.pmid: 18347166
references.citation: J Leukoc Biol. 1994 Nov;56(5):571-5
references.pmid: 7964165
references.citation: J Pharmacol Exp Ther. 2008 Aug;326(2):423-31
references.pmid: 18502982
references.citation: Br J Haematol. 2005 Jun;129(6):755-62
references.pmid: 15953001
references.citation: Leukemia. 2012 Nov;26(11):2326-35
references.pmid: 22552008
references.citation: J Urol. 2007 Dec;178(6):2378-83; discussion 2383-4
references.pmid: 17936848
references.citation: Cancer Chemother Pharmacol. 2013 Oct;72(4):861-8
references.pmid: 23975329
references.citation: Clin Cancer Res. 2002 Aug;8(8):2505-11
references.pmid: 12171876
references.citation: Br J Haematol. 2005 Jun;129(6):776-83
references.pmid: 15953004
references.citation: Planta Med. 2010 Aug;76(11):1064-74
references.pmid: 20186654
references.citation: Nat Rev Mol Cell Biol. 2011 Jun 23;12(7):439-52
references.pmid: 21697901
references.citation: Clin Breast Cancer. 2010 Dec 1;10(6):465-70
references.pmid: 21147690
references.citation: Leuk Res. 2013 Nov;37(11):1502-8
references.pmid: 24075534
references.citation: Cancer Chemother Pharmacol. 2011 Dec;68(6):1439-47
references.pmid: 21479634
references.citation: Oncogene. 1999 Jan 28;18(4):943-53
references.pmid: 10023670
references.citation: Clin Cancer Res. 2012 Sep 1;18(17):4830-40
references.pmid: 22761464
references.citation: Oncogene. 2005 Jan 13;24(3):419-30
references.pmid: 15543232
references.citation: Curr Cancer Drug Targets. 2011 Mar;11(3):239-53
references.pmid: 21247388
references.citation: Eur J Cancer. 2013 Jan;49(2):290-6
references.pmid: 23058787
references.citation: Lancet Oncol. 2011 May;12(5):431-40
references.pmid: 21507715
references.citation: Blood. 2009 Jun 4;113(23):5927-37
references.pmid: 19190249
references.citation: Leuk Res Treatment. 2013;2013:705714
references.pmid: 23738080
references.citation: Blood. 2008 Sep 1;112(5):1593-9
references.pmid: 18574024
references.citation: Clin Cancer Res. 2013 Apr 15;19(8):2248-56
references.pmid: 23447001
references.citation: Eur J Haematol. 2011 Jan;86(1):23-31
references.pmid: 20874823
references.citation: Ann Pharmacother. 2013 Jan;47(1):56-62
references.pmid: 23300152
references.citation: Biochem Pharmacol. 2012 Jan 15;83(2):207-17
references.pmid: 22027222
references.citation: Blood. 2010 Sep 2;116(9):1460-8
references.pmid: 20505158
references.citation: Cell Death Differ. 1999 Apr;6(4):303-13
references.pmid: 10381632
references.citation: J Clin Oncol. 2010 Dec 1;28(34):5101-9
references.pmid: 20940200
references.citation: Blood. 2013 Nov 7;122(19):3276-82
references.pmid: 24004667
references.citation: Science. 2000 May 12;288(5468):1053-8
references.pmid: 10807576
references.citation: Int J Biochem Cell Biol. 2012 Nov;44(11):1729-38
references.pmid: 22819849
references.citation: Br J Haematol. 2009 Mar;144(6):895-903
references.pmid: 19170677
references.citation: Clin Cancer Res. 2011 May 1;17(9):2734-43
references.pmid: 21364033
references.citation: Curr Pharm Des. 2013;19(22):4025-38
references.pmid: 23181572
references.citation: J Clin Oncol. 2005 Feb 1;23(4):676-84
references.pmid: 15613699
references.citation: Angew Chem Int Ed Engl. 2012 Aug 27;51(35):8708-20
references.pmid: 22711561
references.citation: Am J Hematol. 2009 Jan;84(1):6-14
references.pmid: 18980173
references.citation: J Clin Oncol. 2002 Nov 15;20(22):4420-7
references.pmid: 12431963
references.citation: Blood. 2010 Jan 21;115(3):475-80
references.pmid: 19965689
references.citation: Nat Cell Biol. 2003 May;5(5):373-6
references.pmid: 12724766
references.citation: Cancer. 2006 Dec 1;107(11):2688-97
references.pmid: 17075878
references.citation: Drug Resist Updat. 1999 Aug;2(4):215-223
references.pmid: 11504494
references.citation: Ann Oncol. 2006 May;17(5):813-7
references.pmid: 16403809
references.citation: Curr Top Microbiol Immunol. 2002;268:73-89
references.pmid: 12083009
references.citation: Curr Cancer Drug Targets. 2011 Mar;11(3):254-84
references.pmid: 21247382
references.citation: Blood. 2012 May 10;119(19):4391-4
references.pmid: 22331188
references.citation: Blood. 2012 Aug 30;120(9):1801-9
references.pmid: 22665938
references.citation: Blood. 2011 Jan 13;117(2):500-9
references.pmid: 20956804
references.citation: Chem Biol. 2011 Nov 23;18(11):1401-12
references.pmid: 22118674
references.citation: Nat Rev Drug Discov. 2006 Jul;5(7):596-613
references.pmid: 16816840
references.citation: Physiol Rev. 2002 Apr;82(2):373-428
references.pmid: 11917093
references.citation: Biochim Biophys Acta. 2014 Jan;1843(1):13-25
references.pmid: 23994620
references.citation: Blood. 2011 Jul 28;118(4):865-73
references.pmid: 21562045
references.citation: Nat Med. 2011 Nov 06;17(12):1636-40
references.pmid: 22057347
references.citation: J Clin Oncol. 2011 Sep 1;29(25):3396-401
references.pmid: 21810681
references.citation: Leukemia. 2009 Sep;23(9):1679-86
references.pmid: 19369963
references.citation: Cell Mol Life Sci. 1999 Dec;56(11-12):908-17
references.pmid: 11212325
references.citation: Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):183-93
references.pmid: 11316563
references.citation: Cancer. 2010 Dec 1;116(23):5432-9
references.pmid: 20665890
references.citation: Mol Cancer Ther. 2010 Jul;9(7):2026-36
references.pmid: 20606045
references.citation: Br J Haematol. 2008 Nov;143(4):537-40
references.pmid: 18783399
references.citation: J Natl Compr Canc Netw. 2013 May;11(5 Suppl):676-9
references.pmid: 23704241
references.citation: J Clin Oncol. 2004 Sep 15;22(18):3720-5
references.pmid: 15365068
references.citation: Clin Cancer Res. 2011 Aug 15;17(16):5311-21
references.pmid: 21724551
references.citation: Br J Haematol. 2009 Sep;146(6):619-26
references.pmid: 19622094
references.citation: Blood. 2010 Apr 22;115(16):3416-7
references.pmid: 20413666
references.citation: Blood. 2010 Dec 2;116(23):4906-15
references.pmid: 20805366
references.citation: Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6111-8
references.pmid: 15447997
references.citation: Curr Opin Cell Biol. 1995 Apr;7(2):215-23
references.pmid: 7612274
references.citation: Chem Biol. 2012 Jan 27;19(1):99-115
references.pmid: 22284358
references.citation: Chem Rev. 2007 Mar;107(3):687-717
references.pmid: 17316053
references.citation: Chem Biol. 2012 Apr 20;19(4):467-77
references.pmid: 22520753
references.citation: Oncogene. 2012 May 10;31(19):2373-88
references.pmid: 21996736
references.citation: Clin Pharmacokinet. 2012 Dec;51(12):823-9
references.pmid: 23018466
references.citation: Lung Cancer. 2010 Apr;68(1):89-93
references.pmid: 19524318
references.citation: Eur J Haematol. 2013 Apr;90(4):263-72
references.pmid: 23311753
references.citation: Blood. 2009 Oct 29;114(18):3960-7
references.pmid: 19713465
references.citation: Nature. 1997 May 15;387(6630):299-303
references.pmid: 9153396
references.citation: J Clin Oncol. 2012 Aug 20;30(24):2946-55
references.pmid: 22802322
references.citation: Leuk Lymphoma. 2007 Jul;48(7):1313-9
references.pmid: 17613759
references.citation: Kidney Int. 2003 Feb;63(2):501-13
references.pmid: 12631115
references.citation: Haematologica. 2013 Nov;98(11):1753-61
references.pmid: 23935022
references.citation: Semin Hematol. 2012 Jul;49(3):228-42
references.pmid: 22726546
references.citation: Blood. 2007 Nov 1;110(9):3281-90
references.pmid: 17591945
references.citation: Neurotoxicology. 2013 Dec;39:124-31
references.pmid: 24035926
references.citation: Clin Lung Cancer. 2005 Oct;7 Suppl 2:S64-6
references.pmid: 16250930
references.citation: Clin Cancer Res. 2006 Feb 15;12(4):1270-5
references.pmid: 16489083
references.citation: Br J Haematol. 2004 Oct;127(2):165-72
references.pmid: 15461622
references.citation: Kidney Int. 1999 Jul;56(1):118-34
references.pmid: 10411685
references.citation: Br J Haematol. 2008 May;141(4):512-6
references.pmid: 18371113
references.citation: Blood. 2011 Mar 10;117(10):2807-12
references.pmid: 21239695
references.citation: Leukemia. 2009 Jul;23(7):1337-41
references.pmid: 19225538
references.citation: Leukemia. 2002 Apr;16(4):433-43
references.pmid: 11960320
references.citation: Neurotox Res. 2010 Feb;17(2):167-78
references.pmid: 19609631
references.citation: Haematologica. 2007 Oct;92(10):1302-7
references.pmid: 18024367
references.citation: J Biomed Biotechnol. 2011;2011:978312
references.pmid: 21765642
references.citation: Br J Haematol. 2010 Mar;148(5):810-2
references.pmid: 19919649
references.citation: Cancer Sci. 2009 Feb;100(2):341-8
references.pmid: 19068089
references.citation: Drug Metab Dispos. 2011 Oct;39(10):1873-82
references.pmid: 21752943
references.citation: J Biol Chem. 1998 May 15;273(20):12148-54
references.pmid: 9575161
references.citation: Ann Oncol. 2009 Mar;20(3):520-5
references.pmid: 19074748
references.citation: Crit Rev Oncol Hematol. 2014 Nov;92(2):61-70
references.pmid: 24890785
references.citation: Cancer Cell. 2012 Sep 11;22(3):345-58
references.pmid: 22975377
references.citation: Blood. 2012 Sep 27;120(13):2581-8
references.pmid: 22889759
references.citation: Trends Biochem Sci. 1996 Jun;21(6):208-14
references.pmid: 8744354
references.citation: Haematologica. 2007 Oct;92(10):1411-4
references.pmid: 17768111
references.citation: Cancer Invest. 2007 Dec;25(8):733-7
references.pmid: 17952740
references.citation: Mol Cancer Ther. 2013 Feb;12(2):195-206
references.pmid: 23243061
references.citation: J Biol Chem. 2011 May 20;286(20):17682-92
references.pmid: 21454712
references.citation: Biologics. 2013;7:13-32
references.pmid: 23386784
references.citation: Cancer Cell Int. 2010 Apr 29;10:12
references.pmid: 20429927
references.citation: Clin Cancer Res. 2013 Sep 1;19(17):4559-63
references.pmid: 23775332
references.citation: Proc Natl Acad Sci U S A. 1990 Sep;87(18):7071-5
references.pmid: 2205851
references.citation: Blood. 2008 Sep 15;112(6):2489-99
references.pmid: 18565852
references.citation: Clin Cancer Res. 2009 Nov 15;15(22):7085-91
references.pmid: 19903785
references.citation: J Natl Cancer Inst. 2011 Jul 6;103(13):1007-17
references.pmid: 21606441
references.citation: J Clin Oncol. 2010 Oct 20;28(30):4621-9
references.pmid: 20823406
references.citation: Nat Med. 1997 Feb;3(2):231-4
references.pmid: 9018245
references.citation: Nat Med. 2009 Jul;15(7):781-7
references.pmid: 19525961
references.citation: J Clin Oncol. 2011 Feb 20;29(6):690-7
references.pmid: 21189393
references.citation: J Clin Oncol. 2004 Jun 1;22(11):2108-21
references.pmid: 15169797
references.citation: Blood. 2010 May 27;115(21):4168-73
references.pmid: 20124509
references.citation: Nat Rev Cancer. 2004 May;4(5):349-60
references.pmid: 15122206
references.citation: Curr Cancer Drug Targets. 2011 Mar;11(3):285-95
references.pmid: 21247387